IPO Panel:  Targanta Therapeutics Corporation

9 Key Opinion Leaders in Infectious Disease Discuss Oritavancin

Moderated by:  Heather Stein, MD, Vice President, Research Services

October 5, 2007

Deliverable: Transcripts with key findings.

Project Objectives

§    Clinical opinions about Oritavancin and its potential therapeutic applications

§    The current antibiotic landscape into which Oritavancin is being introduced

§    The results of recent studies presented at ICAAC 2007 detailing the activity of Oritavancin against its targeted organisms such as Staphylococcus (including MRSA), Streptococcus, and Enterococcus (including VRE)

§    Other potential clinical applications for Oritavancin including treatment of Clostridium difficile

§    Factors affecting the adoption of Oritavancin into clinical practice

§    The FDA approval process and any potential obstacles

Companies and Products Mentioned in This Report

Panelists:  U.S based, board-certified KOL’s in infectious disease

Hospitals Represented:

§    Duke University Medical Center, NC

§    University of Pennsylvania School of Medicine, PA

§    The University of Texas Medical School at Houston, TX

§    University of Pittsburgh Medical Center, PA

§    Beth Israel Deaconess Medical Center, MA

§    Barnes-Jewish Hospital, Washington University School of Medicine, MO

§    The Johns Hopkins University School of Medicine, MD

§    Virginia Commonwealth University Medical Center, VA

§    St. Luke's-Roosevelt Hospital Center, Columbia University Medical Center, NY

Reports become free one year after the publication date.